In order to promote academic exchanges and experience sharing of standardized diagnosis and treatment of esophageal cancer, promote the standardization and standardization of diagnosis and treatment of esophageal cancer in my country, and gradually realize standardization, specialization, standardization, refinement and informationization, and ultimately benefit the majority of patients. On April 6, 2022, the second session of the "Immunotherapy Series Lectures" was held online. The conference invited well-known experts in related fields to give lectures on tumor immunotherapy and other related content, and to share the latest research progress.

The meeting was opened and summarized by Professor Zou Liqun from West China Hospital of Sichuan University and Professor Li Wenyu from Guangdong Provincial People's Hospital. Prof. Zhitao Ying from Peking University Cancer Hospital focused on the interpretation of "Carrier Screening for CAR-T Cell Therapy"; Prof. Qi Deng from Tianjin First Central Hospital focused on sharing "CD19 CAR in refractory follicular lymphoma complicated with liver metastasis" -T Cell Therapy"; Professor He Mingmin from West China Hospital of Sichuan University explained "Lymphoma Case Sharing in West China Hospital"; then, all the participating experts had a stimulating discussion based on the content of the meeting.

This conference provides a platform for clinical medical practitioners and scientific researchers to exchange diagnosis and treatment technologies and academic scientific research results, which is conducive to academic discussions and exchanges of classic cases and cutting-edge technologies in immunotherapy, and establishes a comprehensive and standardized immunotherapy medical treatment platform. idea. It is of great significance to promote high-quality clinical research in the field of medical oncology and promote the level of clinical scientific research.